Clinical trials: Schizophrenia; Psychosis
Schizophrenia
Assess the Safety and Pharmacokinetics of Ascending, Multiple Oral Doses of SPD489 in Adults With Schizophrenia
This is a multiple ascending dose study; the purpose of this study is to examine the safety, tolerability and pharmacokinetics (levels of drug in the blood) of SPD489 in Schizophrenic Patients who are currently maintained on a…
- Trial name
- NCT01457339
- Testing
- SPD489 (Lisdexamfetamine dimesylate)
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Shire
Schizophrenia
Antipsychotic Augmentation With L-Dopa
Dopamine, a chemical in the brain, has been linked to schizophrenia for a number of years. More recently, there is evidence that certain areas affected in schizophrenia (e.g.
- Trial name
- NCT01636037
- Testing
- levodopa/carbidopa (generic version of Sinemet)
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Cognitive Behavioral Social Skills Training for Patients With Late-Life Schizophrenia: a Pilot Study
Schizophrenia is associated with significant cognitive and functional deficits. As patients with schizophrenia grow older, the impact of these deficits at a personal and public health level is likely to increase.
- Trial name
- CBSST (NCT00832845)
- Testing
- CBSST plus treatment as usual, Treatment as usual (TAU)
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
The purpose of the study was an Open Label Extension to the recurrence prevention study to evaluate long-term safety and tolerability of paliperidone ER in subjects with schizophrenia.
- Trial name
- NCT00645307
- Testing
- Extended Release OROS® Paliperidone
- Volunteers
- 235 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Tardive Dyskinesia
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Tardive dyskinesia (TD) is a well-known complication of antipsychotic drug therapy in individuals treated for mental disorders such as schizophrenia.
- Trial name
- NCT00621634
- Testing
- Omega-3 fish oil capsules (including DHA)
- Where
- 2 sites in Canada
- Sponsor
- Université de Montréal
Paranoid Schizophrenia, Schizophrenia
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
The purpose of this study is to determine the safety and effectiveness of an investigational drug for the treatment of cognitive impairment in patients with schizophrenia.
- Trial name
- NCT00482430
- Testing
- MK0557
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia, Bipolar I Disorder
Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder
Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced…
- Trial name
- DAiP (NCT03630822)
- Testing
- Psychiatric Advanced Directive, Standard care
- Where
- France
- Volunteers
- 399 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia
30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.
- Trial name
- NCT00409201
- Testing
- reboxetine adjuvant therapy
- Where
- 2 sites in Israel
- Volunteers
- 30 people
- Sponsor
- Abarbanel Mental Health Center
Schizophrenia, Schizoaffective Disorder
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia.
- Trial name
- NCT02034474
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- New York State Psychiatric Institute
First Episode Psychosis
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
- Trial name
- NCT04046497
- Testing
- Smartphone App, Usual Care
- Where
- 5 sites in United States
- Volunteers
- 139 people
- Sponsor
- Northwell Health
Bipolar and Related Disorders
Enhancing Cognitive Reserve of the Offsprings of Bipolar and Schizophrenic Patients
The high hereditary component and the contribution of neurodevelopmental processes in bipolar disorder and schizophrenia means implies the children of these patients are considered a high risk population for both diseases and…
- Trial name
- NCT03722082
- Testing
- Enhancing Cognitive Reserve, Support intervention
- Where
- Spain
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Nurses, Schizophenia Disorder
The Effectiveness of Combining AR/VR Technology in Virtual Clinical Auditory Hallucinations on the Comprehensive Auditory Hallucination Nursing Competency of Psychiatric Nurses
This study aims to develop and evaluate a Virtual Reality (VR) Auditory Hallucination Program to enhance psychiatric nurses' comprehensive care competence in managing auditory hallucinations among patients with schizophrenia.
- Conditions
- Nurses, Schizophenia Disorder, Hallucinations, Auditory
- Trial name
- NCT06938997
- Testing
- Virtual clinical auditory hallucination solution combining AR/VR technology, Auditory Hallucination Care Video
- Where
- 4 sites in Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia
A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate
The purpose of this study is to evaluate the change of medication satisfaction measured by Medication Satisfaction Questionnaire (MSQ) from baseline to endpoint for patients who are switched into paliperidone palmitate, either…
- Trial name
- NCT01682161
- Testing
- Paliperidone palmitate
- Where
- 9 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination
Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimulation which uses a very weak constant current to temporarily excite the brain area of interest via small electrodes placed on the scalp.
- Trial name
- NCT02426983
- Testing
- Direct Current Stimulation, Dextromethorphan
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Ottawa
Schizophrenia
Genetic Research in Schizophrenia Using DNA Markers and Clinical Phenotypes
Schizophrenia has long been known to be an illness with significant evidence for a genetic predisposition. The purpose of this study is to determine the genetic abnormalities that cause childhood and adult onset schizophrenia.
- Trial name
- NCT00108303
- Testing
- Diagnostic
- Where
- United States
- Volunteers
- 538 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia
The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with…
- Trial name
- NCT00567203
- Testing
- PF-3463275
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Schizophrenia
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of a 6 weeks memantine add-on to risperidon treatment for the prevention of cognitive dysfunction and negative symptomatology in patients with acute schizophrenia.
- Trial name
- NCT00148590
- Testing
- Memantine
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- M. Schaefer, MD
Schizophrenia
Prucalopride for Cognitive Functioning in Schizophrenia
A core component of schizophrenia is neurocognitive impairment. The cognitive deficits are prominently seen in memory, attention, working memory, problem solving, processing speed and social cognition.
- Trial name
- NCT06474286
- Testing
- Prucalopride 1 MG
- Where
- India
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Recent-Onset Psychosis, Schizophrenia
Multifamily Psychoeducation and Cognitive Remediation for Recent-Onset Psychosis
The goal of this study is to determine whether pairing multifamily group psychoeducation with cognitive remediation may facilitate improved outcomes among individuals with recent-onset psychosis.
- Conditions
- Recent-Onset Psychosis, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features
- Trial name
- NCT01196286
- Testing
- Multifamily Group Psychoeducation (MFG), Cognitive Remediation (CR)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Schizophrenia
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)
This is a Phase 3, multicenter, 53-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in subjects with Diagnostic and Statistical Manual-Fifth Edition (DSM-5)…
- Trial name
- NCT04659174
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 44 sites in United States, Ukraine
- Volunteers
- 152 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.